These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
8. Persistent docetaxel-induced supravenous erythematous eruption. Fernandes Kde A; Felix PA An Bras Dermatol; 2015; 90(5):728-30. PubMed ID: 26560218 [TBL] [Abstract][Full Text] [Related]
9. Erythematous-to-brownish plaques on the upper back: a quiz. Phenytoin-induced T-cell predominant pseudolymphoma (“pseudomycosis fungoides”) with T-cell clonality. Toberer F; Hartschuh W; Kutzner H; Flux K Acta Derm Venereol; 2015 Mar; 95(3):378-82. PubMed ID: 25111894 [No Abstract] [Full Text] [Related]
11. Non-pigmenting fixed drug eruption induced by sorafenib. Tanabe K; Amoh Y; Mii S; Eto H; Iwamura M; Katsuoka K Acta Derm Venereol; 2010 May; 90(3):307. PubMed ID: 20526556 [No Abstract] [Full Text] [Related]
12. Generalized fixed drug eruption caused by pazufloxacin. Sawada Y; Nakamura M; Tokura Y Acta Derm Venereol; 2011 Sep; 91(5):600-1. PubMed ID: 21597677 [No Abstract] [Full Text] [Related]
13. Fixed drug eruption (phenolphthalein). Evidence for a blood-borne mediator. Wyatt E; Greaves M; Sondergaard J Arch Dermatol; 1972 Nov; 106(5):671-3. PubMed ID: 4117910 [No Abstract] [Full Text] [Related]
14. Persistent supravenous erythematous eruption: a rare local complication of intravenous 5-fluorouracil therapy. Pujol RM; Rocamora V; Lopez-Pousa A; Taberner R; Alomar A J Am Acad Dermatol; 1998 Nov; 39(5 Pt 2):839-42. PubMed ID: 9810911 [TBL] [Abstract][Full Text] [Related]
15. Eczema-like, erythematous, infiltrated plaques: a common side effect of subcutaneous heparin therapy. Klein GF; Kofler H; Wolf H; Fritsch PO J Am Acad Dermatol; 1989 Oct; 21(4 Pt 1):703-7. PubMed ID: 2530252 [TBL] [Abstract][Full Text] [Related]
17. Symmetric ptychotropic and nonpigmenting fixed drug eruption due to cimetidine (so-called baboon syndrome). Helmbold P; Hegemann B; Dickert C; Marsch WC Dermatology; 1998; 197(4):402-3. PubMed ID: 9873190 [No Abstract] [Full Text] [Related]
18. Cutaneous drug eruption with an interface dermatitis pattern due to anti-tumour necrosis factor-alpha agents: a relevant class-effect. Garcovich S; Burlando M; Rongioletti F; Garcovich A; Parodi A; Amerio P Acta Derm Venereol; 2010 May; 90(3):311-2. PubMed ID: 20526559 [No Abstract] [Full Text] [Related]
19. [Secondary drug toxiderma to acenocoumarol]. Khammassi N; Kessentini N Pan Afr Med J; 2015; 22():95. PubMed ID: 26848342 [No Abstract] [Full Text] [Related]
20. Is cetuximab-induced rash conclusion really a remnant of the skin erythema dose? Oskan F; Belka C; Manapov F Int J Radiat Oncol Biol Phys; 2013 Nov; 87(3):462-3. PubMed ID: 24074919 [No Abstract] [Full Text] [Related] [Next] [New Search]